RemeGen Secures US\$650 Million Upfront Payment from AbbVie in Landmark RC148 Licensing Agreement

Key Highlights

• RemeGen Co., Ltd. has received a US\$650 million upfront payment from AbbVie Inc. as part of an exclusive licensing agreement for RC148.
• The agreement grants AbbVie exclusive rights to develop, manufacture, and commercialize RC148 outside Greater China.
• RemeGen is eligible to receive up to US\$4.95 billion in additional milestone payments covering development, regulatory, and commercial achievements.
• The agreement also includes tiered double-digit royalty payments based on net sales of RC148 outside Greater China.
• RC148 is a novel PD-1/VEGF targeting bispecific antibody drug, independently developed by RemeGen.
• The licensing agreement took effect on March 10, 2026, and the collaboration is progressing smoothly.

Details of the Transaction

On January 12, 2026, RemeGen Co., Ltd. entered into an exclusive license agreement with AbbVie Inc., which became effective on March 10, 2026. Under the terms, AbbVie receives exclusive rights to the development, manufacturing, and commercialization of RC148 outside of Greater China. In exchange, RemeGen has now received a substantial US\$650 million upfront payment from AbbVie, a significant capital inflow that bolsters the company’s financial position.

In addition to the upfront payment, RemeGen stands to gain up to US\$4.95 billion in further milestone payments, contingent on the achievement of specified development, regulatory, and commercial objectives. Furthermore, RemeGen will earn tiered double-digit royalties on net sales of RC148 outside Greater China, presenting a long-term revenue stream.

Strategic and Financial Impact

This agreement not only provides immediate financial benefit through the substantial upfront payment but also positions RemeGen for significant future revenues. The magnitude of the potential milestone payments and royalties suggests a high level of confidence from AbbVie in the commercial prospects of RC148.

The upfront receipt of US\$650 million is a material event that strengthens RemeGen’s balance sheet, enabling further investment in research, development, and potential new product pipelines. The partnership with a global pharmaceutical leader like AbbVie also validates RemeGen’s technological capabilities and increases the visibility of its innovative drug candidates.

Shareholder Considerations and Price-Sensitive Information

• The successful receipt of the upfront payment is a major positive financial event for RemeGen and could have a significant impact on its share price.
• The future potential for milestone and royalty payments introduces meaningful long-term revenue potential, which could materially affect the company’s valuation.
• The partnership with AbbVie, a major industry player, enhances RemeGen’s credibility and global footprint, potentially attracting further strategic interest or investment.
• Shareholders should note the smooth progression of the collaboration, suggesting positive operational momentum and reduced execution risk.

Board and Management

The announcement was made by Mr. Wang Weidong, Chairman and Executive Director of RemeGen, with the board comprising a mix of executive, non-executive, and independent directors, highlighting a strong governance structure.

Conclusion

The upfront payment from AbbVie represents a significant financial and strategic milestone for RemeGen. The size of the deal, the potential for further milestone and royalty payments, and the validation by a global leader like AbbVie are all likely to be price-sensitive events with the capacity to move RemeGen’s share price. Investors should closely watch further developments in the RC148 program and the ongoing collaboration for additional value creation.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. Investors should conduct their own research or consult a professional advisor before making investment decisions.

View REMEGEN Historical chart here